Explore the NIHProtocol Details
A Pilot Trial of YF476, A Gastrin Antagonist, in Patients with Type II Gastric Carcinoids Associated with Zollinger-Ellison Syndrome
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
11-DK-0114 |
Sponsoring Institute |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
No |
Population Exclusion(s) |
Children |
Special Instructions |
Currently Not Provided |
Keywords |
Gastrin Antagonist; |
Recruitment Keyword(s) |
Zollinger-Ellison Syndrome; |
Condition(s) |
Carcinoid |
Investigational Drug(s) |
YF476 |
Investigational Device(s) |
None |
Intervention(s) |
Drug: YF476 |
Supporting Site |
|
- Zollinger-Ellison syndrome (ZES) is a rare condition in which one or more tumors (gastrinomas), usually in the small intestine or pancreas, produce high levels of the hormone gastrin. High levels of gastrin can cause several problems: (1) excessive growth of stomach cells; (2) excessive production of stomach acid, which can cause stomach or intestinal ulcers; and (3) growth of an unusual type of stomach tumor called a type II gastric (i.e., stomach) carcinoid. Patients with ZES suffer mainly from the effects of severe ulcer disease, but gastrinomas and gastric carcinoids both have the potential to spread throughout the body. Gastric surgery is the usual treatment for problematic carcinoids. YF476, an experimental medication, may block the effects of gastrin, which may reduce the need for surgery as well as provide better control of stomach acid in patients with ZES. Researchers are interested in studying YF476 in individuals with ZES who also have or may develop type II gastric carcinoids.
Objectives:
- To evaluate the safety and effectiveness of YF476 in reducing the size, number, or significance of type II gastric carcinoids or their precancerous cells.
- To study the effects of YF476 on stomach acid production.
Eligibility:
- Individuals at least 18 years of age who have been diagnosed with Zollinger-Ellison syndrome and type II gastric carcinoids or their precancerous cells.
Design:
- This study will involve a screening visit and five study visits.
- Participants will be screened with a physical examination and medical history, as well as blood tests.
- At the first study visit, participants will have an initial measurement of stomach acid production (gastric acid analysis) and an upper endoscopy to collect biopsies of esophagus, stomach, and small intestine tissue. Participants will receive YF476 to take by mouth once per day with food, and will be asked to keep a diary of medication doses, changes in symptoms, and any possible new symptoms or problems.
- After 3 weeks, participants will have another study visit with a physical examination, blood and urine tests, and questions about current condition and any side effects.
- After another 3 weeks (6 weeks after starting YF476), participants will have another gastric acid analysis and an upper endoscopy with biopsies. Participants may be eligible to receive a higher dose of YF476 if the endoscopy and biopsies show no significant change (decreased size and/or number of carcinoids or precancerous cells). If the stomach is completely normal at this visit on endoscopy and biopsy, participants will stop taking the study drug.
- After another 6 weeks (12 weeks after starting YF476), participants will have another physical examination, blood and urine tests, and an upper endoscopy with biopsies. YF476 will be stopped. Participants who show improvement after treatment will have a final followup visit. Participants who do not show improvement will not have the followup visit, but may be asked to return for additional clinic visits to check for side effects from YF476.
- The final visit will be a followup visit 12 weeks after the end of treatment with YF476. Participants who responded to YF476 will have blood tests and an upper endoscopy with biopsies.
Eligibility
INCLUSION CRITERIA:
1. Men; post-menopausal women; pre-menopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy; or premenopausal women using one of the allowed methods of contraception: condom and spermicide or intra-uterine device.
2. The first 10 patients will have confirmed ZES (elevated gastrin, acid hypersecretion, abnormal secretin test), treated with a PPI, and endoscopically visible gastric carcinoids; subsequent patients will have confirmed ZES (treated with a PPI) and gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
3. Patients with serum gastrin > 250 pg/mL.
4. Hepatic function: AST and ALT less than or equal to 2.0 times ULN; total bilirubin less than or equal to 1.0 times ULN.
5. Renal function: serum creatinine < 1.0 times ULN.
6. Haematologic function: Hb greater than or equal to 10.0 g/dL; WBC greater than or equal to 3.5 times 10(9)/L; ANC greater than or equal to 1.5 times 10(9)/L; platelets greater than or equal to 100 times 10(9)/L.
7. Coagulation parameters: INR or PT less than or equal to 1.0 times ULN; PTT less than or equal to 1.0 times ULN.
8. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
9. Willingness to give fully-informed, written consent.
EXCLUSION CRITERIA:
1. Patients under 18 years.
2. Women who are pregnant, lactating or using a steroid contraceptive.
3. Prior gastric resection or bypass.
4. Planned gastrinoma resection during the study period.
5. Patients on somatostatin analogues, except for those on therapy for greater than or equal to 6 months with stable or worsening carcinoids
6. Inability to tolerate endoscopy, or refusal of endoscopy.
7. Physical findings, ECG (especially prolonged QTc interval > 450 msec), or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.
8. Certain medicines and herbal remedies taken during the 7 days before Visit 2.
9. Participation in a trial of an IMP within the previous 28 days.
10. Presence of drug or alcohol abuse.
11. History or baseline findings of:
- Type I diabetes mellitus;
- Pancreatitis (baseline amylase and/or lipase greater than or equal to 2.0 times the ULN);
- Hepatitis B, hepatitis C or HIV;
- malabsorption syndrome or inability to swallow or retain oral medicine;
- Major surgery less than or equal to 28 days prior to enrollment;
- ECOG performance status greater than or equal to 2; or
- Another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in-situ.
- Also, any clinically significant and uncontrolled major morbidity including but not limited to: serious cardiac disease (unstable angina, s/p myocardial infarction less than or equal to 1 month); respiratory disease (advanced COPD or pulmonary fibrosis); uncontrolled hypertension; or active systemic infection.
12. Medically documented ongoing psychiatric illness, unless determined to be an acceptable candidate by an NIH psychiatric consultant.
13. Inability to give informed consent.
Citations:
Contacts:
Principal Investigator |
Referral Contact |
For more information: |
| Stephen A. Wank, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health BG 10 RM 9C101 10 CENTER DR BETHESDA MD 20814 (301) 496-4202 stevew@bdg10.niddk.nih.gov |
Stephen A. Wank, M.D. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health BG 10 RM 9C101 10 CENTER DR BETHESDA MD 20814 (301) 496-4202 stevew@bdg10.niddk.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT01322542
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
